Navigating the Diagnostic Process

Confirming a diagnosis of aromatase deficiency requires a “detective work” approach. Because the condition is so rare, a single blood test is rarely enough; instead, doctors look for a specific pattern across hormone panels, genetic sequencing, and specialized imaging.

The Urgent Priority: Ruling Out CAH

When a newborn presents with atypical genital development, the immediate medical priority is ensuring the infant is safe from Congenital Adrenal Hyperplasia (CAH) ^[1]. The workup for CAH must happen immediately and typically involves testing electrolytes, glucose, blood pressure, cortisol, ACTH, 17-OHP, and renin/aldosterone. A normal newborn screen does not reliably rule out all forms of CAH, so urgent clinical evaluation is necessary ^[2].

The Hormone Signature

Once CAH is ruled out, the body’s hormone levels provide the clues. In aromatase deficiency, the brain “sees” that there isn’t enough estrogen and sends increasingly loud signals to the ovaries or testes to produce more ^[3].

• Estrogens (Estradiol and Estrone): These are typically extremely low or undetectable ^[4]. It is important that labs use a highly sensitive method called LC-MS/MS (Liquid Chromatography-Mass Spectrometry), as standard tests may not be sensitive enough to detect the very low levels present ^[5].
• Gonadotropins (FSH and LH): These “messenger” hormones from the brain are usually elevated. Gonadotropins vary by age, pubertal stage, and treatment, and should be interpreted against age- and sex-appropriate reference ranges and the overall clinical picture ^[3][6].
• Androgens (Testosterone and Androstenedione): Because these cannot be converted into estrogen, they “backup” in the system. They may be elevated, though this varies from person to person ^[3][7].
• Adrenal Steroids: Tests like 17-hydroxyprogesterone (17-OHP) and cortisol are usually checked to assess adrenal function. The exact workup depends on age, symptoms, prior results, and specialist judgment ^[8][1].

Confirming with Genetic Testing

The diagnosis is supported by genetic testing to find mutations in the CYP19A1 gene ^[9].

• Biallelic Variants: To have the condition, a person must have “pathogenic” (disease-causing) variants on both copies of the gene—one from each parent ^[10].
• Testing Methods: Doctors typically use direct DNA sequencing to look for small “typos” in the gene. If sequencing comes back with only one mutation (or none) but symptoms strongly suggest the condition, they may use deletion/duplication analysis to look for larger missing chunks of DNA ^[10][2]. Note that genetic testing can miss some variants, and finding a “Variant of Uncertain Significance” (VUS) does not automatically establish the diagnosis or justify treatment.

Imaging: Looking for Physical Clues

Imaging helps doctors see how the hormone imbalance is affecting the organs and the skeleton. These are clinician-selected monitoring tools, individualized based on age, anatomy, and symptoms.

• Pelvic Ultrasound (for 46,XX individuals): This is used to look at the uterus and ovaries. Findings can vary widely: some individuals have very small (hypoplastic) ovaries, normal ovaries, or develop large ovarian cysts as they get older ^[6][7].
• Bone Age X-rays: This simple X-ray of the hand and wrist determines the “age” of the bones. In both individuals with this condition, the bone age is often much younger than the person’s actual age because the growth plates have not received the estrogen signal to close ^[6][11].
• DXA Scan: This measures bone mineral density (BMD). It is a clinician-selected test used to check for osteopenia (low bone mass) or osteoporosis, which are common because estrogen is necessary to build strong bones. Pediatric results should generally be reported with age- and size-adjusted Z-scores ^[8][4].

The Completeness Checklist

If you are currently undergoing a diagnostic workup, a specialist may consider collecting the following data points based on your specific situation:

1. Karyotype: To confirm if the chromosomal pattern is 46,XX or 46,XY.
2. Sensitive Estrogen Panel: Estradiol and estrone measured via LC-MS/MS.
3. Gonadotropin Levels: Both FSH and LH interpreted in context.
4. Adrenal Screen: Comprehensive assessment to urgently rule out CAH if presenting in a newborn, guided by a specialist.
5. CYP19A1 Sequencing: Confirmation of biallelic (two) mutations.
6. Pelvic Ultrasound: To document the state of ovaries and uterus (for 46,XX) when clinically indicated.
7. Skeletal Baseline: Clinician-timed bone age X-ray and a DXA scan for bone density.
8. Parental Testing: To confirm the parents are carriers and that the two mutations are “in trans” (one on each chromosome) ^[9].